Mortality among urban drug users and the impact of highly active antiretroviral therapy

Clinical Infectious Diseases

Volumn 41, Issue 6, 2005, Pages 873-874

  Celentano, David D ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CAUSE OF DEATH; DRUG USE; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MORTALITY; NONBIOLOGICAL MODEL; NONHUMAN; NOTE; PATIENT COMPLIANCE; PRIORITY JOURNAL; SEXUAL BEHAVIOR; SUBSTANCE ABUSE; SURVIVAL RATE; URBAN AREA; VIRUS LOAD;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; HIV INFECTIONS; HUMANS; SUBSTANCE ABUSE, INTRAVENOUS; URBAN POPULATION;

EID: 24644513792     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/432895     Document Type: Note

References (15)

1. Detels R, Munoz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS an death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 1998; 280:1497-503.
2. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119-29.
3. Murphey EL, Collier AC, Kalish LA, et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001; 135:17-26.
4. Poundstone K, Chaisson RE, Moore RD. Differences in HIV disease progression by injection drug use and sex in the era of highly active antiretroviral therapy. AIDS 2001; 15:1115-23.
5. Whitman S, Murphy J, Cohen M, et al. Marked declines in human immunodeficiency virus related mortality in Chicago in women, African Americans and injection drug users 1995-1997. Arch Intern Med 2000; 160:365-9.
6. Kohli R, Lo Y, Howard AA, et al. Mortality in an urban cohort of HIV-infected and at-risk drug users in the era of highly active antiretroviral therapy. Clin Infect Dis 2005; 41:864-72 (in this issue).
7. Schoenbaum EE, Hartel D, Selwyn PA, et al. Risk factors for human immunodeficiency virus infection in intravenous drug users. N Engl J Med 1989; 321:874-9.
8. Wang CL, Vlahov D, Galai N, et al. Mortality among HIV-seropositive vs. seronegative persons in the HAART era: implications for when to initiate therapy. J Infect Dis 2004; 190:1046-54.
9. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-60.
10. Mocroft A, Madge S, Johnson AM, et al. A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival. J Acquir Immune Defic Syndr 1999; 22:369-78.
11. Smith DK, Gardner LI, Phelps R, et al. Mortality rates and causes of death in a cohort of HIV-infected and uninfected women, 1993-1999. J Urban Health 2003; 80:676-88.
12. Riley ED, Bangsberg DR, Guzman D, Perry S, Moss AR. Antiretroviral therapy, hepatitis C virus, and AIDS mortality among San Francisco's homeless and marginally housed. J Acquir Immune Defic Syndr 2005; 38:191-5.
13. Vlahov D, Galai N, Safaeian M, et al. Effectiveness of highly active antiretroviral therapy among injection drug users with late-stage human immunodeficiency virus infection. Am J Epidemiol 2005; 161:999-1012.
14. Celentano DD, Vlahov D, Cohn S, Shadle VM, Obasango O, Moore RD. Self-reported antiretroviral therapy in injection drug users. JAMA 1998; 280:544-6.
15. Strathdee SA, Palepu A, Cornelisse PG, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA 1998; 280:547-9.